EVT:NYE-Eaton Vance Tax Advantaged Dividend Income Closed Fund (USD)

FUND | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 23.94

Change

-0.32 (-1.32)%

Market Cap

N/A

Volume

0.18M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.04 (+1.93%)

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.20 (+1.44%)

USD 43.37B
HLN Haleon plc

+0.18 (+1.82%)

USD 43.18B
RDY Dr. Reddy’s Laboratories Ltd..

-0.09 (-0.67%)

USD 11.49B
ELAN Elanco Animal Health

-0.11 (-0.99%)

USD 5.69B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.04 (-0.51%)

USD 3.63B
BHC Bausch Health Companies Inc

+0.13 (+1.81%)

USD 2.41B
DHBUF Delivra Health Brands Inc

+0.11 (+744.67%)

USD 5.54M
CPHI China Pharma Holdings Inc

-0.01 (-4.59%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+1.47%)

USD 1.96M

ETFs Containing EVT

FCEF First Trust Income Opport.. 0.00 % 0.85 %

-0.13 (0.00%)

USD 0.04B
E908:F 0.00 % 0.00 %

N/A

N/A
EXS2:F 0.00 % 0.00 %

N/A

N/A
E908:XETRA 0.00 % 0.00 %

N/A

N/A
EXS2:XETRA 0.00 % 0.00 %

N/A

N/A
EXIB:XETRA 0.00 % 0.00 %

N/A

N/A
CB1TX:SW Lyxor 1 TecDAX (DR) UCITS.. 0.00 % 0.00 %

N/A

N/A
TDXPEX:SW iShares TecDAX® UCITS ET.. 0.00 % 0.00 %

N/A

USD 5,933.97B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.46% 67% D+ 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.46% 67% D+ 29% F
Trailing 12 Months  
Capital Gain 6.07% 67% D+ 54% F
Dividend Return 7.24% 100% F 85% B
Total Return 13.31% 67% D+ 63% D
Trailing 5 Years  
Capital Gain -8.24% 62% D 40% F
Dividend Return 33.66% 100% F 86% B+
Total Return 25.42% 69% C- 51% F
Average Annual (5 Year Horizon)  
Capital Gain 6.13% 43% F 54% F
Dividend Return 12.75% 64% D 65% D
Total Return 6.63% 100% F 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 25.46% 57% F 43% F
Risk Adjusted Return 50.09% 86% B+ 63% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike